{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:37:04Z","timestamp":1777012624390,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antisynthetase syndrome (ASS) is a systemic autoimmune disorder classified as a subtype of the idiopathic inflammatory myopathies (IIM). The condition is defined by the presence of mutually exclusive autoantibodies directed against an aminoacyl-tRNA synthetase along with typical clinical manifestations, including myositis, Raynaud\u2019s phenomenon, arthritis, skin lesions such as mechanic hands, or interstitial lung disease (ILD). Anti-synthetase syndrome associated interstitial lung disease (ASS-ILD) can range from mild forms to rapidly progressive disease, which may lead to chronic pulmonary damage if misdiagnosed or inadequately treated. Patients with IIM carry an increased risk of developing neoplasms, most commonly adenocarcinoma, but not lymphoma or other hematologic malignancies. However, data on the association between ASS and malignancy remain very limited. We report the case of a patient with anti-PL-12 antisynthetase syndrome who subsequently developed NK\/T-cell non-Hodgkin lymphoma, supplemented by a review of the pertinent literature.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1761119","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:41:11Z","timestamp":1777009271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Anti-PL-12 Antisynthetase syndrome complicated by natural killer\/T cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Kun","family":"Li","sequence":"first","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-E","family":"Liang","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Yu","family":"Guo","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA synthetases: On anti-synthetase syndrome and beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2233","article-title":"Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature","volume":"135","author":"Kalluri","year":"2009","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: A single centre cohort study","volume":"40","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.08.021","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease","volume":"85","author":"Antoniou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead671","article-title":"Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centered retrospective cohort study","volume":"64","author":"Tang","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 european league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome - much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/rheumatology\/keae403","article-title":"Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: A systematic literature review","volume":"64","author":"Kouranloo","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: An international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12283","article-title":"The five major autoimmune diseases increase the risk of cancer: Epidemiological data from a large-scale cohort study in China","volume":"42","author":"Zhou","year":"2022","journal-title":"Cancer Commun (Lond Engl)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and Malignancy: A comprehensive review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allerg Immu"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.024","article-title":"Hematological Malignancy associated with polymyositis and dermatomyositis","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04428-z","article-title":"Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with Malignancy: A 25-year retrospective study","volume":"39","author":"Motomura","year":"2019","journal-title":"Rheumatol Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.amjmed.2025.05.042","article-title":"Association of cancer and anti-synthetase syndrome: A retrospective multicenter study","volume":"138","author":"Bucy","year":"2025","journal-title":"Am J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i22.6435","article-title":"Manifestation of severe pneumonia in anti-PL-7 antisynthetase syndrome and B cell lymphoma: A case report","volume":"9","author":"Xu","year":"2021","journal-title":"World J Clin cases"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaf111.095","article-title":"P066 more than meets the eye: a unique case of anitisynthetase syndrome with peripheral T-cell lymphome","volume":"9","author":"Krishnan","year":"2025","journal-title":"Rheumatol Adv Pract"},{"key":"B24","article-title":"Unsuspected lymphomatoid granulomatosis in a patient with antisynthetase syndrome","volume":"100","author":"Skala","year":"2017","journal-title":"Cutis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi341","article-title":"Immune-related conditions and immune-modulating medications as risk factors for non-hodgkin\u2019s lymphoma: A case-control study","volume":"162","author":"Engels","year":"2005","journal-title":"Am J Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-1070","article-title":"Altered immunity as a risk factor for non-hodgkin lymphoma","volume":"16","author":"Grulich","year":"2007","journal-title":"Cancer Epidemiology Biomarkers Prevention: A Publ Am Assoc For Cancer Research Cosponsored by Am Soc Prev Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01313-2","article-title":"NK-\/T-cell lymphomas","volume":"35","author":"Wang","year":"2021","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116270","article-title":"Treatment of epstein-barr virus infection in immunocompromised patients","volume":"225","author":"Pociupany","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42494","article-title":"A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061414","article-title":"EBV and the pathogenesis of NK\/T cell lymphoma","volume":"13","author":"Montes-Mojarro","year":"2021","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","article-title":"Viral oncogenesis in cancer: From mechanisms to therapeutics","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduction Targeted Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1761119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:41:22Z","timestamp":1777009282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1761119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1761119"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1761119","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1761119"}}